Schorno Dean L 4

What Happened
Dean L. Schorno, Chief Financial Officer of Rigel Pharmaceuticals (RIGL), was credited with a performance-based stock option covering 7,394 shares on June 17, 2026. The Form 4 reports an acquisition of 7,394 derivative securities at $0.00 (code A). The option's exercise price is $22.49 per share (set at grant), and the vesting occurred because a performance metric was satisfied on June 17, 2026.

Key Details

• Transaction date: June 17, 2026 — reported on Form 4 filed June 22, 2026.
• Reported transaction: Award/vesting of a stock option covering 7,394 shares (derivative securities), acquisition price shown as $0.00.
• Exercise price: $22.49 per share (set at grant on January 29, 2025).
• Vesting: The option was fully vested on June 17, 2026 when the performance condition was met (per footnotes).
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: The Form 4 was filed five days after the transaction date (appears late versus the usual two-business-day reporting requirement).
• Footnotes: F1 explains the option was granted 1/29/2025 with performance-based vesting; F2 confirms the option fully vested on 6/17/2026.

Context

• This report reflects a vesting/award of a stock option (derivative), not a cash purchase or a sale. There is no indication in the filing that the option was exercised or that any shares were sold immediately.
• For retail investors, vesting of performance-based awards signals the company recorded achievement of whatever internal metric triggered the grant; it is not a direct buy/sell signal by the insider.